Medera Inc

Founded in 2014, Medera is a clinical-stage company dedicated to next-generation cell and gene therapies for difficult-to-treat and incurable diseases. Mederas preclinical and clinical programs target a range of cardiac, vascular and muscular indications, including Heart Failure with preserved Ejection Fraction (HFpEF), Duchenne Muscular Dystrophy and Pulmonary Hypertension, etc. Medera operates via its 2 subsidiaries: Novoheart (www.linkedin.com/company/novoheart-limited) is responsible for Disease Modelling & Drug Discovery using our proprietary, award-winning mini-Heart Technology, which offers a range of bioengineered human heart constructs including the worlds first human heart-in-a-jar as healthy and diseased human hearts for testing toxicity and efficacy. This platform enables us to uniquely model human-specific diseases and discover therapeutic candidates all in the context of human cells and tissues, free from species-specific differences. Before privatisation by Meder...